Fruquintinib May Edge Ahead in KRAS-Mutant Colorectal Cancer, But No Clear Winner Yet

For patients with metastatic colorectal cancer whose tumors carry a KRAS mutation, the final lines of therapy have long been a guessing game. Three oral drugs—regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102)—are all approved for use after standard treatments fail, yet none has ever been tested against another in a head-to-head randomized trial. A new systematic review and Bayesian network meta-analysis, published in Frontiers in Oncology, has now pulled together the placebo-controlled trial evidence to ask which of these agents performs best, both in the overall population and specifically in the KRAS-mutant subgroup that accounts for roughly one-third of all colorectal cancers.

The research team, led by investigators at Beijing University of Chinese Medicine and Peking University Third Hospital, systematically searched PubMed, Embase, and the Cochrane Library through 6 November 2025. From an initial haul of 1,180 records, they identified ten randomized controlled trials encompassing 3,959 patients with metastatic colorectal cancer who had progressed after second-line therapy. Each trial compared one of the three oral agents—alone or, in some cases, TAS-102 combined with bevacizumab—against placebo or best supportive care. Risk of bias was assessed with the Cochrane RoB-2 tool, and the protocol was prospectively registered with PROSPERO.

Because no trial has ever randomized patients directly between regorafenib, fruquintinib, and TAS-102, the researchers turned to network meta-analysis, a statistical framework that uses a common comparator—in this case placebo—to make indirect comparisons across trials. They fitted a Bayesian random-effects consistency model with non-informative normal priors, ran four parallel Markov chains through 20,000 adaptation iterations and 50,000 sampling iterations, and confirmed convergence using the Gelman-Rubin diagnostic. The resulting network was star-shaped, anchored on placebo, with no closed loops among the active treatments, which meant formal inconsistency testing was impossible; instead, the team relied on transitivity checks comparing trial characteristics and potential effect modifiers.

The headline finding for the overall population was straightforward: every active treatment significantly prolonged overall survival compared with placebo. Fruquintinib produced a hazard ratio of 0.66 (95% credible interval 0.53–0.84), regorafenib 0.69 (0.51–0.88), TAS-102 0.69 (0.55–0.85), and TAS-102 plus bevacizumab 0.41 (0.28–0.59). The combination of TAS-102 with bevacizumab ranked first by SUCRA—the surface under the cumulative ranking curve—while the three single agents showed broadly similar efficacy, with indirect differences among them not consistently statistically significant. Progression-free survival followed the same pattern, with all experimental arms outperforming placebo and the doublet again delivering the largest benefit.

One indirect comparison did stand out: fruquintinib showed a more favorable progression-free survival than TAS-102, with a hazard ratio of 0.65 (95% CrI 0.45–0.96), placing it highest among the monotherapies. The authors caution, however, that this estimate rests entirely on indirect evidence in the absence of head-to-head trials and should be interpreted cautiously. Heterogeneity also varied considerably across the network: it was essentially absent for fruquintinib versus placebo (I² ≈ 0%), moderate for TAS-102 (OS I² = 21.8%), and high for regorafenib (OS I² = 67.5%, PFS I² = 83.1%), prompting the use of random-effects models throughout.

The most novel contribution of the analysis lies in its KRAS stratification. During transitivity checks, KRAS mutational status emerged as the most plausible source of the between-study heterogeneity, driven largely by differences in baseline KRAS prevalence—Asian trials such as CONCUR and TERRA enrolled 34% and 37% KRAS-mutant patients respectively, while the remaining trials ranged from 40% to 70%. When the team restricted the analysis to trials reporting KRAS-subgroup overall survival data, heterogeneity collapsed dramatically in the wild-type subgroup, with I² falling to 20% or below for every comparison, and the three agents ranked almost side by side with no meaningful differences between them.

In the KRAS-mutant subgroup, the picture shifted subtly. Fruquintinib and TAS-102 each produced numerically favorable overall survival estimates versus placebo—hazard ratios of 0.71 (95% CrI 0.51–1.01) and 0.74 (95% CrI 0.50–0.99) respectively—whereas regorafenib did not reach statistical significance, with a hazard ratio of 0.81 (95% CrI 0.52–1.19). The exploratory ranking placed fruquintinib first, TAS-102 second, and regorafenib last. The authors are emphatic, however, that these differences in statistical significance versus placebo do not demonstrate superiority of fruquintinib or TAS-102 over regorafenib, and that the rank probabilities are hypothesis-generating rather than evidence of a predictive effect of KRAS status.

The mechanistic backdrop helps explain why KRAS status might matter. KRAS is mutated in approximately 40% of colorectal cancers, driving constitutive RAS signaling and unrestrained cell growth. Prior laboratory work has suggested that exon-2 KRAS mutations, particularly G12C and G12A, maintain elevated BRAF-ERK-ELK phosphorylation and blunt regorafenib-induced apoptosis and vessel shutdown, while a recently described KRAS/ERK2–TRIM21–c-Myc/ENO2 glycolytic axis promotes regorafenib resistance. Notably, among the three TAS-102 trials, the Japanese phase 2 study by Yoshino and colleagues showed a markedly stronger benefit in KRAS-mutant patients (hazard ratio 0.44) than in wild-type disease (0.70), a pattern that largely accounts for the residual heterogeneity in that treatment node.

The combination of TAS-102 with bevacizumab emerged as the standout regimen overall. Mechanistically, the pairing is plausible: trifluridine inhibits thymidylate synthase and, through its metabolite FTY, becomes incorporated into DNA causing miscoding, while tipiracil protects trifluridine from degradation by blocking thymidine phosphorylase; bevacizumab, meanwhile, suppresses VEGF-driven angiogenesis and remodels the tumor microenvironment. The authors suggest these mechanisms may act synergistically, and a separate analysis indicated the combination conferred a particularly pronounced survival benefit in RAS-mutant patients (hazard ratio 0.38, 95% CrI 0.19–0.79) with no significant advantage over monotherapy in the wild-type population—though only one study contributed to that subgroup node, precluding a stable network estimate.

The study has clear limitations that the authors acknowledge candidly. No head-to-head randomized comparisons exist among the three agents, the star-shaped network precluded formal inconsistency testing, and individual-participant data were unavailable, so a formal treatment-by-KRAS interaction test could not be performed. Comparative safety was not formally meta-analyzed because safety definitions and reporting thresholds differed substantially across trials, and progression-free survival subgroup analysis was abandoned due to insufficient sample size and high heterogeneity (I² ranging from 77.7% to 92.2%). Publication-bias testing was deemed unreliable with fewer than ten trials per outcome. The authors conclude that for KRAS-wild-type patients, standard third-line regimens or TAS-102 plus bevacizumab are reasonable, while for KRAS-mutant patients fruquintinib may represent a sensible later-line option—pending confirmation from prospective, KRAS-stratified or head-to-head trials that the field has yet to deliver.

Subject of Research: Comparative efficacy of third-line oral therapies for KRAS-mutant metastatic colorectal cancer

Article Title: Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis

Article References: Zhou, Y., Zhao, S., Zheng, X., Wang, Y., Wang, M., Chen, S., Wu, Z., Zang, D., & Si, W. (2026). Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis. Frontiers in Oncology, 16, Article 1948508. https://doi.org/10.3389/fonc.2026.1948508

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1948508

Keywords: fruquintinib, regorafenib, TAS-102, KRAS mutation, metastatic colorectal cancer, network meta-analysis, overall survival, progression-free survival, bevacizumab, third-line therapy, precision oncology, Bayesian analysis